Introduction / Background
The Deepwater Horizon oil spill has led to the use of large amounts of dispersant as part of the integrated approach dealing with the oil spill. Given this fact, questions have arisen about the toxicity of the chemicals used as dispersants themselves. EPA's Office of Research and Development (ORD) was asked to carry out rapid studies to provide information on the potential for toxicity of eight commercially available dispersants. Because some of the dispersants reportedly include nonylphenol ethoxylates (NPEs) that can degrade to isomers of nonylphenol (NP), some of which are proven estrogenic compounds, the potential endocrine effects of the dispersants are of particular concern. For example, NPEs and NPs have been demonstrated to be endocrine disruptors in fish [1] . In response to the request ORD has undertaken a series of shortterm in vitro studies to determine if any of the dispersants displayed estrogenic, androgenic or other endocrine activity.
ORD developed a strategy to address the questions of endocrine activity and relative toxicity as rapidly as possible. ORD scientists initiated several complementary studies of eight oil spill dispersants being used or considered for use in the Gulf. The issue was to provide some targeted information on the dispersants as quickly as possible. In vitro assays are well suited for that purpose. This work complements a study of whole animal toxicity in small fish and brine shrimp also being carried out by ORD. The results of that study are being simultaneously released with this report.
One set of studies used a set of mammalian in vitro reporter gene assays in estrogenresponsive and androgen-responsive cells [2, 3] run in-house at ORD laboratories in RTP, NC.
Additional studies were conducted by two external labs (NIH Chemical Genomics Center
[NCGC] and Attagene Inc.) to run mammalian in vitro reporter gene assays to measure androgen and estrogen-response activity. A panel of 74 assays against non-endocrine molecular targets was also included in the Attagene assays. The NCGC and Attagene assays are part of the EPA ToxCast program [4, 5] . All assays evaluated the eight dispersants Corexit GOLD. The performance of the assays was characterized by simultaneously running positive and negative control chemicals. Quantitative cytotoxicity measurements were carried out on each of the cell types used. All data analyses and interpretation were carried out by ORD staff.
It is important to note that positive results in vitro only demonstrate that a chemical is a potential endocrine disruptor and that follow-up tests will likely be needed in order to refine or confirm the endocrine activity. For example, effects seen in vitro may not be expressed in vivo, so additional studies would need to be conducted to verify the in vitro results and determine if the potential activity was displayed in whole animals and the dosage levels required to affect organisms.
.
Project Goals
1. Determine if any of the eight dispersants displayed estrogenic, androgenic or antiandrogenic activity in vitro using a variety of well characterized in vitro cell-based assays that utilize different approaches for detecting endocrine driven gene expression changes 2. Determine the dispersant concentration that induced cytotoxicity in multiple cell lines and derive an aggregate measure of cytotoxicity that could be use to rank order the chemicals and to compare with in vivo toxicity data obtained in aquatic test species.
Study Summary:
One part of the project was carried out by ORD researchers in partnership with the NIH Chemical Genomics Center [NCGC] and Attagene Inc. Two high throughput assay sets were run on the dispersants, a collection of reference chemicals for ER and AR activity, plus nonylphenol compounds. In addition to assays for AR and ER, this phase of the project produced data on a battery of other transcription factor assays which are part of multiplexed panels including AR and ER assays. Cytotoxicity was evaluated in three cell lines over a range of concentrations.
The other phase of the study was carried out in-house by ORD researchers using multiple assays [2, 3] to measure interaction between the eight dispersants plus reference chemicals and ER or AR. In particular, this work evaluated the eight dispersants for estrogen agonist activity in an estrogen-responsive transcriptional activation assays (ER-TA), for androgen agonist activity in two androgen-responsive transcriptional activation assays (AR-TA), MDA-kb2 and CV-1 assays and for androgen antagonist activity in the MDA-kb2 assay in competition with 1 nM Dihydrotestosterone (DHT). Cytotoxicity was evaluated in each assay at every concentration by both a biochemical assay which assessed metabolic perturbation and by a visual assessment of cytopathic effect on cell viability and morphology.
Chemicals
All assays evaluated eight commercially available oil spill dispersants that were obtained directly from the respective manufacturers. EPA chose these eight dispersants from the dispersants listed on the National Contingency Plan Product Schedule based on three criteria: 1) lower toxicity of the dispersant or of the dispersant when mixed with oil; 2) availability of sufficient quantities to respond to the Gulf spill; and 3) immediate availability of samples for testing. These included Corexit In the in-house ORD assays, a 17-Estradiol (E2; 50-28-2) dose response was included on every plate in the ER-TA assay as a positive control. 4-Nonylphenol (branched) (84852-15-3; Fluka) and 17-Trenbolone (Osaka Hayashi Pure Chemical Industries Ltd., CAS no. 80657-17-6, purity 99.9%) were also tested in the estrogen mediated assays. A dihydrotestosterone (DHT; Sigma Chemical; CAS 55206-14-9) dose response was included as a positive control on every plate in the AR-TA assays. The potent androgen, 17-Trenbolone, was also tested in the androgen agonist assays. Dosing solutions of dispersants and reference compounds were prepared on-site under observation of a Quality Assurance manager. The assays used in the NHEERL assays have been demonstrated [2, 8] to give appropriate responses to known estrogenic or androgenic compounds.
Results
More detailed assay protocols and statistical analysis methods can be found in the Appendices, as well as a Quality Assurance (QA) Statement.
Androgen Receptor Agonist Activity AR Agonist Assay 1 Multiplexed reporter transcription unit (RTU) assay
Method Summary: This assay is part of a multiplexed reporter gene panel run by Attagene Inc.
(RTP, NC), under contract to the U.S. EPA (Contract Number EP-W-07-049). This assay consists of 48 human transcription factor DNA binding sites transfected into the HepG2 human liver hepatoma cell line as previously described [9] . This trans assay employs a mammalian onehybrid assay consisting of an additional 25 RTU library reporting the activity of nuclear receptor (NR) superfamily members. The human ligand-binding domain of each nuclear receptor was expressed as a chimera with the yeast GAL4 DNA-binding domain that activated in trans a 5XUAS-TATA promoter, which regulated the transcription of a reporter sequence unique to each NR RTU. To ensure the specificity of detection, each individual trans-RTU system including both receptor and reporter gene was separately transfected into suspended cells followed by pooling and plating of the transfected cells prior to screening. The trans assay evaluates changes in activities of exogenous, chimeric NR-Gal4 proteins. This particular assay evaluated transcription for the Androgen receptor, and uses the code ATG_AR_TRANS.
Additional detail of the method is provided in the Appendix B.1. Concentration-response titration points for each compound were fitted as described in Appendix C. For this analysis, there were either 4 replicates in 16 concentrations, except for SAF-RON GOLD which was only tested in 2 replicates and 8 concentrations.
Results: No activity was seen for any of the dispersants
AR Agonist Assay 2 AR betalactamase Assay
Method Summary: This assay was run at the NIH Chemical Genomics Center (NCGC; Rockville, MD) in collaboration with EPA as part of the Tox21 collaboration [10] . A betalactamase reporter-gene cell-based assay [GeneBLAzer ® AR-UAS-bla-GripTite™ assay developed by Invitrogen] was used to measure AR ligand signaling. AR-UAS-bla-GripTite™ HEK 293 cells (AR bla cells) were used with assay medium containing 10% dialyzed FBS, 0.1 mM NEAA and 1 mM sodium pyruvate. The assay was performed in clear bottom black Greiner 1536-well plates. R1881, a synthetic androgen agonist, was used as a positive control in the screen. Library compounds were measured for their ability to either stimulate or inhibit the reporter gene activity. Compounds were screened in a titration series in 1536-well format. The fluorescence intensity (405 nm excitation, 460/530 nm emission) was measured using an EnVision plate reader. Data was normalized relative to R1881 control (40 nM, 100%, for agonist mode and 10 nM, 0%, for antagonist mode), and DMSO only wells (basal, 0% for agonist mode and -100% for antagonist mode). Additional detail of the method is provided in the Appendix B.2. Concentration-response titration points for each compound were fitted as described in in all of these assays were significantly greater than the values for positive control chemicals, and in the antagonist assays, this dispersant looked like a "super-activator" rather than an antagonist. All of this data taken together indicates strongly that some non-specific activation is occurring that is independent of ER or AR. We have found previously that compounds identified as promiscuous "super-activators" in multiple beta-lactamase reporter gene assays with a narrow potency range (a <3-fold difference in potency is within the experimental variations of these assays) are mostly auto fluorescent (R Huang, unpublished data). Thus, the activity observed for JD 2000 is likely an artifact of the beta-lactamase assay format. Preliminary results from three additional beta-lactamase assays for non-steroid receptor targets all showed the JD 2000 "super-activation". Considering the totality of the data, we conclude that JD 2000 does not exhibit ER or AR transactivation activity. To further confirm that this JD 2000 activity is non-specific and not due to ER or AR activation, we are running several follow-up assays with NCGC: known antiestrogens and antiandrogens are being used to show that JD 2000 activity is not suppressed; and we will complete our analysis of results for the the three non-steroid receptor beta-lactamase assays are being run with JD 2000 to show that this non-specific activity occurs independent of ER and AR. 
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AR Agonist Assay 4 CV1 transient transcription assay
Method Summary: This assay run in-house by NHEERL is similar to the MDA-kb2 in that it also assesses the ability of a compound to mimic an androgen. This assay, however, uses CV-1 cells which do not express either endogenous androgen or estrogen receptors. In contrast to the MDAkb2 assay, both the androgen receptor and the androgen responsive MMTV promoter-luciferase reporter constructs are introduced into the CV-1 cells for each assay via transient transfection.
Nine concentrations of each dispersant were tested for agonist activity in both AR-TA assays.
Each concentration was tested in quadruplicate. The first dilution of each sample was a 1:100 dilution (i.e. 0.01 dilution or 10,000 ppm) of the dispersant in cell culture medium followed by eight additional 10-fold serial dilutions. Method details are provided in the Appendix F. an effect which we interpreted to result from cytotoxicity at 10 ppm, the highest concentration used in this assay. would explain the absence of observable activity for these dispersants in the cis assay, because we do not consider curves with EMax values below 2. The other curves in the bottom panels of Figure 6 show data for NP and NPE compounds, described below. Nonylphenol-related activity: It is known that some of the dispersants contain NPEs. Our initial hypothesis was that any estrogenic activity detected for the complex mixtures could be due to the NPEs or to NP itself generated by in situ degradation of the NPE, or residual contamination from synthesis of the NPE. Consequently, we tested two nonylphenols (one linear and one branched, technical grade) and two commercial NPEs in the Attagene assays. Table 2 shows the results of this analysis, and Figure 6 shows the corresponding dose-response curves for the Attagene ER assays. From these data, one can see that these cell-based assays show ER activity for both the To summarize this section, estrogen receptor (ER) activity was observed in two of the dispersants in the Attagene trans-ER assay (ZI-400 and Nokomis 3-F4), although at relatively high concentrations and with low efficacy (EMax). We have also shown that NPs and NPEs are also active in the trans-ER assay. Therefore, the activity in ZI-400 and Nokomis 3-F4 is suggestive of the presence of an NP or NPE as part of the mixture. We know that this is the case with ZI-400. The ER effect seen for these dispersants is weak, which is also suggestive of there being only a relatively small amount of NPE or some other estrogenic substance in the total mixture.
ER Agonist Assay 2 Multiplexed reporter transcription unit (RTU) cis assay
(RTP, NC), under contract to the U.S. EPA (Contract Number EP-W-07-049). This assay consists of 48 human transcription factor DNA binding sites transfected into the HepG2 human liver hepatoma cell line as previously described [9] . A major difference between the cis and trans system is that in cis activities of endogenous transcription factors are measured. This particular assay evaluated transcription for the Estrogen receptor element (ERE), and uses the code ATG_ERE_CIS. For this analysis, there were either 4 replicates in i6 concentrations, except for SAF-RON GOLD which was only tested in 2 replicates and 8 concentrations. Additional detail of the method is provided in the Appendix B.1. Concentration-response titration points for each compound were fitted as described in Appendix C.
Results: No statistically significant activity was seen for any of the dispersants

ER Agonist Assay 3 -ERalpha betalactamase Assay
Method Summary: This assay was run at the NIH Chemical Genomics Center (NCGC;
Rockville, MD) in collaboration with EPA as part of the Tox21 collaboration [10] . A betalactamase reporter-gene cell-based assay [ER-UAS-bla GripTite 
ER Agonist Assay 4 T47DKBluc estrogenresponsive transcriptional activation assay
Method Summary: T47D-KBluc, is an estrogen receptor-mediated transcriptional activation assay (ER-TA) that detects the ability of chemicals to mimic estrogen [8] . This assay was run in- Results: The ability of the eight dispersants to stimulate luciferase expression in this cell line was compared to 17β-Estradiol (CAS 50-28-2: a concentration-response curve to E2 was included on each 96 well plate with the dispersants) and to 4-Nonylphenol (branched) (CAS 84852-15-3) (Figure 7 a,b) . 17α-Trenbolone (CAS 80657-17-6) was run as a negative control herein ( Figure   7d ) and as a positive control in the assessment of androgenicity. None of the eight dispersants displayed any potential estrogenicity (i.e. did not simulate luciferase induction) at any concentration in the current investigation (Figure 8) . In fact, all the dispersants significantly reduced luciferase levels at high concentrations due to cytotoxicity. 
Cytotoxicity Assay 2 -AR bla Cells
Method Summary: Cell viability after compound treatment was measured in these AR bla cells using a luciferase-coupled ATP quantitation assay (CellTiter-Glo viability assay, Promega). This assay was run by the NIH Chemical Genomics Center. The change of intracellular ATP content indicates the number of metabolically competent cells after compound treatment. The cells were dispensed at 2,000 cells/5 L/well for AR bla cells in 1,536-well white/solid bottom assay plates using an FRD. The cells were incubated for 5 hrs at 37C, followed by the addition of compounds using the pin tool. The final concentration range for reference compounds was 11 pM to 92 M, and 0.000144 ppm to 1209.8 ppm for dispersants. The assay plates were incubated for 16 hrs at 37C, followed by the addition of 5 L/well of CellTiter-Glo reagent. After 30 min incubation at room temperature, the luminescence intensity of the plates was measured using a ViewLux plate reader (PerkinElmer). Data was normalized relative to DMSO only wells (0%), and tetra-n-octylammonium bromide (92 M, -100%). LC50 values were determined by fitting curves as described in Appendix C. Results of cytotoxicity assessment are shown below. For this analysis, there were 8-10 replicates in 24 concentrations.
Cytotoxicity Assay 3 -ER bla Cells
Method Summary: Cell viability after compound treatment was measured in these ER bla cells using a luciferase-coupled ATP quantitation assay (CellTiter-Glo viability assay, Promega). This assay was run by the NIH Chemical Genomics Center. The change of intracellular ATP content indicates the number of metabolically competent cells after compound treatment. The cells were dispensed at 5,000 cells/5 L/well for ER bla cells in 1,536-well white/solid bottom assay plates using an FRD. The cells were incubated a 5 h at 37C, followed by the addition of compounds using the pin tool. The final concentration range for reference compounds was 11 pM to 92 M, and 0.000144 ppm to 1209.8 ppm for dispersants. The assay plates were incubated for 18 hrs at 37C, followed by the addition of 5 L/well of CellTiter-Glo reagent. After 30 min incubation at room temperature, the luminescence intensity of the plates was measured using a ViewLux plate reader (PerkinElmer). Data was normalized relative to DMSO only wells (0%), and tetra-n-octylammonium bromide (92 uM, -100%). LC50 values were determined by fitting curves as described in Appendix C. Results of cytotoxicity assessment are shown below. For this analysis, there were 8-10 replicates in 24 concentrations.
Cytotoxicity Results (Assays 13)
Results of Cytotoxicity Assays 1-3 are summarized below the description of Assays 4-6.
Cytotoxicity Assays 4 THRU 9: measurements in T47DKBluc, MDAkb2, and CV1 cells (MTT and CPE assessments) (5 independent assessments).
Methods summary: The ability of the dispersants to produce a general toxic effect on each of the cell lines used in the in the NHHERL in-house assays was assessed by both observational and biochemical methods. First, each well of cells in every assay was evaluated by visual microscopic examination utilizing a five point cytopathic effect (CPE) criteria scale ranging from 0 (no visual toxicity) to 4 (total cell death). CPE assessment criteria were as follows: 0 = no observed effect; 1= subtle changes suggesting effect; 2 = definite effects or death in a at least 
Cytotoxicity Results (Assays 49)
All eight dispersants disrupted cell function and caused cell death in all three cell lines in the two highest concentrations (0.01 and 0.001, or 10,000 and 1,000 ppm, respectively).
Furthermore, none of the dispersants produced any sign of cytotoxicity at concentrations below 1 ppm (Figures 9-12) . The lowest observed effective concentration (LOEC) for dispersant-induced reductions in MTT, estrogen, androgen and antiandrogen assays are reported in Table 3 . In the table, the noted changes in the two androgen and the estrogen agonist assays do not result from hormone-like increases in luciferase activity but rather represent significant reductions in luciferase expression that likely result from the cytotoxic effects of the dispersants. Statistical significance was determined using analysis of variance followed by t-tests (LSMEANS) using PROC GLM on SAS 9.1 (p< 0.01 was used as the critical value to determine statistical significance). *LOEC (ppm) represents the lowest concentration at which the dispersant consistently reduced the MTT value. Statistical significance was using p<0.01 as determined using LSMEANS option of PROC GLM available on SAS 9.1. ** LOEC concentration was equivocal (nonmonotonic response) *** Antagonist assay for antiandrogens was not run the three highest concentrations (10,000, 1000 and 100 ppm) to avoid most the confounding effects of cell death. The highest concentration was 10 ppm, Dispersants that did not reduce luciferase expression in this assay at any concentration were scored as >10 ppm. Since none of the dispersants displayed any effect interpreted as result of the dispersant displaying endocrine activity we interpret all the results as indications of disruption of cell function and cell death. Since the androgen antagonist assay for antiandrogens did not include the three dispersant highest concentrations (10,000, 1000 and 100 ppm) to avoid most the confounding effects of overt toxicity (seen in the MTT assay with MDA Kb2 cells), the highest concentration in this assay was 10 ppm, Dispersants that did not reduce luciferase expression in this assay at any concentration were scored as >10 ppm. In spite of this precaution, the two most cytotoxic dispersants still reduced luciferase expression in this assay, an effect we attribute to less overt cell toxicity.
MDA
The EC 50 values for the dispersant dose response curves were determined using nonlinear regression procedures with GraphPad Prism 5.0 software (Figure 5 a,b,c) . Ranking the eight dispersants in order of highest to lowest potency in the MTT assays and the CPE assessment in three cells lines indicates that there are some consistent differences among dispersants in their ability to disrupt the function and viability of these cell lines (Figure 5 d) . Dispersant SPC 1000 appears to be more toxic in both MTT (below) and CPE assessments.
Cytotoxicity Summary
For comparison to all of the in vitro cytotoxicity assays, we also include LC50 values from whole animal, aquatic species lethality assays for the mysid, Americamysis bahia, in a 48-hr static acute toxicity test and an inland silverside, Menidia beryllina, 96-hr static acute toxicity test [12] . All In order to assess, statistically, differential cytotoxicity across the eight dispersants we performed an ANOVA to determine pairwise if any two dispersants were more cytotoxic than the other. We performed this statistical test with and without multiple test correction (Bonferroni). For any dispersant and assay combination that did not achieve an LC50, a default value of 3000 ppm was used; three-fold higher than the highest concentration tested in the relevant assays. LC50 values greater than 3000 ppm were also set to this default value to prevent large extrapolated LC50 values from biasing the results. All six cell-based quantitative cytotoxicity assays were used for this analysis. The resulting p-values, raw and corrected, are provided in Table 4 . Both JD 2000 and SAF-RON GOLD tend to be less cytotoxic than the other dispersants. Likewise, DISPERSIT SPC 1000 tends to be more cytotoxic than the other dispersants in the cell-based assays.
The aquatic species LC50 values are almost always lower than the cell-based LC50 values.
As with the cell-based assays, JD 2000 is the least toxic in the whole animal assay. with data on aquatic species from a concurrent EPA report [12] . 
Other Molecular Targets
In addition to ER and AR, we also analyzed the chemical collection (dispersants plus reference chemicals) using a multiplexed reporter gene assay battery that evaluates activity against a panel of transcription factors including nuclear receptors [5, 9] . These assays were run by Attagene Inc. These data also provide a measure of quality control related to the specificity of any endocrine-related activity caused by the dispersants. The description of the assay and a complete list of targets is given in Appendix B.2. All of these assays were carried out twice, one week apart, and in each week, duplicate runs were performed. Figure 14 summarize all of the results for the dispersants. This plot helps illustrate several key points about the data.
First, as the concentration of a chemical approaches the cytotoxic level, generalized cell stress occurs, accompanied by broad misregulation of transcription. When this threshold is reached, many assays in this system simultaneously activate, but this activity is assumed to be non-specific. One sentinel of this cell stress behavior is NRF2, which is an indicator of generalized oxidative stress. Therefore, if we see many assays become active at about the same concentration, especially if NRF2 is among them, we can discount any target specificity above that concentration. We see this behavior for Corexit 9500 (~50 ppm), JD 2000 (~500 ppm), Nokomis 3-AA (~75 ppm), Nokomis 3-F4 (~75 ppm), Sea Brat #4 (~90 ppm) and ZI-400 (~50 ppm).
The ER activity for Nokomis 3-F4 occurs at a concentration well below where this nonspecific behavior is indicated. For ZI-400, the confidence intervals for ER and NRF2 overlap, indicating a possibility that the ER result is non-specific.
The lowest activity that is generally seen is for PXR (Pregnane-X-receptor), which is a xenosensor. This behavior is entirely expected, is common across many classes of organic chemicals, and is not in itself an indicator of toxicity. PXR has been reported to be a xenosensor that acts to protect against endocrine active chemicals [14] . PPAR (peroxisome proliferator activating receptor [15] [16] [17] [18] [19] ) activity is observed for a number of the dispersants, at higher concentrations than is seen for the PXR assays. There is an extensive literature on PPAR activity associated with disease in rodents, although the human relevance is unclear [15] [16] [17] [18] [20] [21] [22] [23] .
However, only for Corexit 9500 and Nokomis 3-AA (and potentially for SAF-RON GOLD) is the PPAR signal well below the level of non-specific activity. Vitamin D receptor (VDR) activity is seen for Sea Brat #4 and Nokomis 3-AA below but near the concentration of nonspecific behavior.
The activity of JD 2000 cannot necessarily be dismissed as being all non-specific, despite it occurring at the same concentration as NRF2 activity. This is because there are only two target families being activated -PXR and PPAR. A similar observation can be made about DISPERSIT SPC 1000. At the concentration of NRF2 activity, we only see activation of two PXR assays and one for SREBP (SREBF1 sterol regulatory element binding transcription factor 1) which is involved in fatty acid synthesis regulation.
The largest effect (in terms of EMax) of any dispersant and assays is for ZI-400 and AhR (Aryl hydrocarbon receptor), with EMax >30. The AhR is well-known for its role in mediating the adaptive metabolism of xenobiotics, and also in the toxicity that follows exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin). This indicates the potential for the presence of a dioxinlike compound, which would be cause for concern. In the ToxCast Phase I data set [4, 5] of 309 chemicals, we saw only three with AhR efficacy higher than is seen with ZI-400. It is not clear though that this effect is specific, given that it occurs in the same concentration range as activity in a number of other targets, and above the NRF2 AC50. The major conclusions of this section are that several of the dispersants display PXR and PPAR activity at concentrations below where cell stress and cytotoxicity occur. These are expected responses in hepatocytes to xenobiotics. The ordering of dispersants by lowest concentration at which bioactivity occurs is consistent with the ordering based on cytotoxicity.
One observation of more general interest is that we are able to detect specific target-based bioactivity in complex mixtures such as these. This is observation is relevant to the challenges of real world chemical toxicity testing, wherein humans and other organisms are often exposed to June 30, 2010 43 complex mixtures rather than the pure single compounds that are the subject of typical toxicity testing.
Conclusions
The primary conclusions are as follows:
For six of the eight dispersants tested we found no evidence that they would be capable of interacting with estrogen or androgen receptor function from testing in multiple in vitro systems.
For the other two dispersants, there was a weak ER signal in one assay. However, integrating over all of the ER and AR results, these data do not indicate that any of the eight dispersants will display biologically significant endocrine activity via the androgen or estrogen signaling pathways. As mentioned previously, NPEs (and their breakdown product NPs) can be endocrine disruptors in fish [1] , so the risk of using NPE-containing dispersants should be carefully weighed against the expected benefits. One limitation of the present study is that there are other routes by which chemicals can cause endocrine disruption, as well as other types of toxicity that have not been tested for here. Most importantly though, there were no indications of estrogenic activity for Corexit 9500, the dispersant currently being used in the Gulf of Mexico.
All of the dispersants showed cytotoxicity in at least one cell type at concentrations between 10 and 1000 ppm. Both JD 2000 and SAF-RON GOLD tend to be less cytotoxic than the other dispersants. Likewise, DISPERSIT SPC 1000 tends to be more cytotoxic than the other dispersants in the cell-based assays. The aquatic species LC50 values tend to be lower than the cell-based LC50 values. As with the cell-based assays, JD 2000 is the least toxic in the whole animal assay.
Supplementary Information
Supplemental information, including a QA Statement, is included in the referenced Appendices.
QA Summary
All research described in this report was conducted under a comprehensive and rigorous program of quality assurance (QA), as documented in the QA supplemental file. The overall goal of the QA program was to ensure research data were of known and acceptable quality. QA staff surveillance of critical research activities was an important feature of the overall QA approach and ensured quick and effective resolution of any problems. The conclusion of the QA review process is that results presented in this report accurately reflect the raw data obtained during the course of the research and are scientifically valid and defensible.
